Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GRHL2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GRHL2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GRHL2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GRHL2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GRHL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GRHL2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GRHL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GRHL2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00351073 | Endometrium | AEH | appendage morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00351083 | Endometrium | AEH | limb morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
GO:00030072 | Endometrium | AEH | heart morphogenesis | 45/2100 | 246/18723 | 6.41e-04 | 6.23e-03 | 45 |
GO:000704310 | Endometrium | AEH | cell-cell junction assembly | 30/2100 | 146/18723 | 7.29e-04 | 6.98e-03 | 30 |
GO:00519739 | Endometrium | AEH | positive regulation of telomerase activity | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
GO:00487366 | Endometrium | AEH | appendage development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:00601736 | Endometrium | AEH | limb development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
GO:00456823 | Endometrium | AEH | regulation of epidermis development | 16/2100 | 65/18723 | 1.81e-03 | 1.44e-02 | 16 |
GO:00605414 | Endometrium | AEH | respiratory system development | 37/2100 | 203/18723 | 1.97e-03 | 1.54e-02 | 37 |
GO:00432979 | Endometrium | AEH | apical junction assembly | 18/2100 | 78/18723 | 2.12e-03 | 1.64e-02 | 18 |
GO:00303246 | Endometrium | AEH | lung development | 33/2100 | 177/18723 | 2.30e-03 | 1.74e-02 | 33 |
GO:00435885 | Endometrium | AEH | skin development | 45/2100 | 263/18723 | 2.58e-03 | 1.90e-02 | 45 |
GO:00604254 | Endometrium | AEH | lung morphogenesis | 13/2100 | 50/18723 | 2.81e-03 | 2.02e-02 | 13 |
GO:00510549 | Endometrium | AEH | positive regulation of DNA metabolic process | 36/2100 | 201/18723 | 3.05e-03 | 2.16e-02 | 36 |
GO:00303236 | Endometrium | AEH | respiratory tube development | 33/2100 | 181/18723 | 3.33e-03 | 2.32e-02 | 33 |
GO:00456043 | Endometrium | AEH | regulation of epidermal cell differentiation | 14/2100 | 58/18723 | 4.12e-03 | 2.73e-02 | 14 |
GO:0030326 | Endometrium | AEH | embryonic limb morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:0035113 | Endometrium | AEH | embryonic appendage morphogenesis | 23/2100 | 116/18723 | 4.58e-03 | 2.95e-02 | 23 |
GO:00607062 | Endometrium | AEH | cell differentiation involved in embryonic placenta development | 8/2100 | 25/18723 | 4.62e-03 | 2.96e-02 | 8 |
GO:00085447 | Endometrium | AEH | epidermis development | 52/2100 | 324/18723 | 5.00e-03 | 3.14e-02 | 52 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GRHL2 | SNV | Missense_Mutation | | c.1627N>T | p.Arg543Trp | p.R543W | Q6ISB3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GRHL2 | SNV | Missense_Mutation | novel | c.1129N>T | p.Asp377Tyr | p.D377Y | Q6ISB3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
GRHL2 | SNV | Missense_Mutation | | c.610N>T | p.Leu204Phe | p.L204F | Q6ISB3 | protein_coding | tolerated(0.73) | benign(0.321) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GRHL2 | SNV | Missense_Mutation | | c.1006G>T | p.Asp336Tyr | p.D336Y | Q6ISB3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
GRHL2 | SNV | Missense_Mutation | | c.1219N>G | p.His407Asp | p.H407D | Q6ISB3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GRHL2 | SNV | Missense_Mutation | | c.667N>A | p.Ala223Thr | p.A223T | Q6ISB3 | protein_coding | tolerated(0.41) | benign(0.01) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
GRHL2 | insertion | In_Frame_Ins | novel | c.426_427insGCCTGGCCTCGTTTTGTTTTTGTTTTTTACAGTGAGACTGAG | p.Ser142_Phe143insAlaTrpProArgPheValPheValPheTyrSerGluThrGlu | p.S142_F143insAWPRFVFVFYSETE | Q6ISB3 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
GRHL2 | insertion | Frame_Shift_Ins | novel | c.458_459insCGTGGTCCTACTTCTAGTGACGCAAGGATCCCATT | p.Gly154ValfsTer17 | p.G154Vfs*17 | Q6ISB3 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
GRHL2 | insertion | Frame_Shift_Ins | novel | c.606_607insGGGTTTCAACACACAGAAACTGCCTTGGCACCAGTGAAGCCCAGAG | p.Tyr203GlyfsTer49 | p.Y203Gfs*49 | Q6ISB3 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GRHL2 | insertion | Frame_Shift_Ins | novel | c.1602_1603insCTCCAGATATTTCTATGCACTCTAAAGTTTGAAAAACATGCTCT | p.Thr535LeufsTer23 | p.T535Lfs*23 | Q6ISB3 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |